| |
American Company Spotlight

|
Cellceutix Corp. Website:
Click Here |
Information As Of
June 23,
2010 |
| Exchange:
OTCBB |
Market Cap:
36.7
Million |
| Outstanding Shares:
91.8
Million |
52 Low / High:
$0.23 / $1.01 |
|
Price June
23, 2010:
$0.45 |
CTIX Recent Stock Quote and News:
Click Here |
"In
in-vivo testing Kevetrin continues to demonstrate consistent
success in fighting drug resistant cancers, the leading cause
of chemotherapy failure" said Mr. George Evans, CEO of the
Company. Mr. Evans continued: “We are optimistic that Kevetrin
will continue to progress on the developmental pathway as a
treatment for these very difficult cancers."
Overview
Cellceutix Corporation is a preclinical cancer, autism and anti-inflammatory
drug developer. Cellceutix owns the rights to eight drug compounds, including
Kevetrin™, which it is developing as a treatment for drug-resistant cancers, and
KM-391, which it is developing for the treatment of autism.
Investment Highlights
- Autism Market Statistics.
Autism Spectrum Disorder is the single fastest
growing developmental disease in the world today with 10 -
17 % annual growth rate. 1% of the United States population,
ages 3 to 17, is afflicted with autism spectrum disorder and
more children will be diagnosed with autism this year than
with AIDS, diabetes & cancer combined. Even with these
stunning facts, there is NO drug available on the market
today that approaches the core issues of autism.
- Cellceutix Autism Compound
Advantages. Cellceutix is developing a novel
compound to address the core issues or autism. Cellceutix is
particularly attractive due to several factors. For
starters, they are the only company with a completely novel
compound, not a derivative of another or a re-application of
an existing. Second, the stock price is only at $.45
currently as they are still “sliding under the radar” while
Novartis and Pfizer are trading at $48 and $15,
respectively.
- Exceptional Animal Studies.
Kevetrin has been performing exceptionally during animal
trials. The Company demonstrated success in more than 5,000 small animal
tests, achieving significant delays in tumor growth compared
to controls in breast, prostate and colon cancer tumors.
- Successful In Fighting Drug
Resistant Cancers. One of the main causes of failure in the treatment of cancer
is the development of drug resistance by the cancer cells.
Kevetrin has been studied against several drug-resistant
cancer cell lines.
- Patent Protection. The Company
announced in May of 2009, that
it had filed a U.S. patent
application covering pharmaceutical formulations of a
compound referred to as Kevetrin and many novel compounds
having similar structures to Kevetrin.
- Successes For Various Cancers.
The Company further proved the benefits of Kevetrin when
they announced that they had successfully completed animal
model tests on a taxane-resistant, estrogen
receptor-negative breast cancer human cell line,
MDA-MB-435s, using its proprietary pharmaceutical compound
Kevetrin™. Tumor volume was reduced by 74% and tumor growth
was delayed by more than 62% compared to controls. In
addition, both the tumor volume reduction and the tumor
growth delay were greater with Kevetrin than with paclitaxel
(Taxol) (p<0.01) or with cisplatin (p<0.01).
- Exceptional Management Experience.
Experience at the top is key for medical Companies, and
Cellceutix's CEO, George Evans has more than 25 years
experience in the Pharmaceutical industry. He worked in a
number of positions for Pfizer Inc., one of the largest
pharmaceutical giants in the world. During his time at
Pfizer Mr. Evans gained experience in all aspects of the
pharmaceutical business, from early stage research to
end-of-life-cycle strategies. Mr. Evans also played a key
part in negotiating several major transactions for Pfizer.
Dr. Krishna Menon, President, has more than 35 years in drug
development for academia and industry. Menon was tapped
Group Leader, Cancer In Vivo Research and Clinical
Development, for Eli Lilly (1995-2001). Lastly, Mr. Ehrlich,
CFO, was a founder of Nanoviricides, Inc. (OTCBB:NNVC).
- Competitive Advantages.
Cellceutix owns the patent and rights to a cancer drug that
has performed better in animal tests than the current
standards of treatment.
Profile
The biotechnology industry is one of the most lucrative of
all industries because of the unique potential to generate
billions of dollars annually with the success of one drug.
Understand that there is always the primary intention of
developing compounds to provide new treatments for diseases
that have areas of unmet need for the good of the species, but
business is still business and revenues certainly have their
place in the overall perspective of things. Investors in
biotechnology generally follow a couple methods in selecting a
company with tremendous upside. One of the primary strategies
is investing in a company involved in HOT areas of research. A
second method is to invest in a niche company with an orphan
or completely novel drug that, if successful, is protected
from competition for several years. Success in these in either
one of these areas will ensure the company and the investor a
faster return and greatly increase the likelihood of a larger
financial windfall for all involved.
This brings us to one of the hottest areas in biotechnology at
this time: autism. Autism Spectrum Disorder is the single
fastest growing developmental disease in the world today with
10 - 17 % annual growth rate. 1% of the United States
population, ages 3 to 17, is afflicted with autism spectrum
disorder and more children will be diagnosed with autism this
year than with AIDS, diabetes & cancer combined. Even with
these stunning facts, there is NO drug available on the market
today that approaches the core issues of autism. There are
many drugs that are manufactured to treat the symptoms that
result from having autism, Ritalin for example, but none that
address the core issues of the autistic brain. Presently,
there is one drug approved by the FDA for use, the
antipsychotic, Risperidone, produced by Johnson & Johnson
which has been approved for use in infantile autism.
Risperidone has not been without its critics, though, as many
question the use of the antipsychotic medication with autistic
infants. With President Obama recently earmarking $1 billion
for studies extending through 2018, biotechnology companies
have recently begun a push to develop compounds seeing both
the great financial and humanitarian benefits that can result
with the successful development of a compound for autism.
From an investor’s standpoint, the two golden rules above
describe why finding companies that are vying for position in
this area can yield great long-term rewards. The research and
development in order to bring one of these drugs to market is
still several years away, but some ground-level entries should
be considered. There are only limited choices presently as to
pharmas that are pulling ahead of the pack in autism drug
research and only ONE that is developing a 100% novel
compound.
Novartis (NYSE: NVS), the German biotech giant, recently
announced that they are conducting research on a compound that
they believe can benefit several areas of illness including
Fragile X Syndrome and autism. While the studies have been
small in scale, the results were promising. In the article
released by www.theautismnews.com in April, Dr. Mark C.
Fishman, president of the Novartis Institutes for BioMedical
Research stated, “We have been reluctant to make this public
because we still need to do more experiments, do them
correctly and in a bigger way,” Dr. Fishman continued, “But
our group feels pretty good about the data.” The compound that
Novartis is researching for autism is an existing compound
that they believe can possibly be re-applied as a treatment
for autism.
Pfizer, Inc. (NYSE: PFE), the largest drug manufacturer in the
world, assembled a 14-member autism research team in 2009.
While Pfizer has not disclosed much about their research, they
seem to be searching for general biological components of the
autistic brain to direct their focus. Issues with
neurotransmitters, more specifically the overabundance of
neural connections, may be a key in addressing core issues of
autism and may hold a key to a treatment. "We've always been
interested in this area but we didn't have the targets," said
Martin Mackay, Pfizer's president of global research and
development, in an interview. Mr. Mackay followed up with,
"Now we do."
Cellceutix Corporation (OTCBB: CTIX) is the dark horse
investment candidate as they continue developments of KM-391,
their compound for the treatment of autism. With a research
team led by Dr. Krishna Menon, who was a Presidential Award
Winner and key researcher for the blockbuster drugs Alimta and
Gemzar during his time at Eli Lilly (NYSE: LLY), Cellceutix is
developing a novel compound to address the core issues or
autism. In a recent press release regarding their preclinical
studies, Dr. Menon stated, “I am very encouraged by the
research results that we are achieving with KM-391 and its
development potential as a treatment for autism. In our
testing, we have simulated specific characteristics of an
autistic brain and behavioral symptoms that result from them.
KM-391 has been shown to significantly improve both the
physical conditions in the brain and behaviors resulting in
our animal models.”
Cellceutix is particularly attractive due to several factors.
For starters, they are the only company with a completely
novel compound, not a derivative of another or a
re-application of an existing. Second, the stock price is only
at $.45 currently as they are still “sliding under the radar”
while Novartis and Pfizer are trading at $49 and $16,
respectively. The potential gains from successful bringing
KM-391 to market are astounding. Finally, Big Pharma has been
historically lacking in research capacities while continually
looking to acquire smaller biotechnology companies with
promising compounds, such as Cellceutix. History may very well
repeat itself in the not too distant future.
Autism research and treatment, is not the only thing that
makes Cellceutix attractive. The Company's flagship product,
Kevetrin™, is being developed to treat cancers that are
resistant to standard treatments. Kevetrin is rapidly
approaching Phase 1 human trials with a target date set for
the fourth quarter of this year. All required FDA pre-clinical
research has been completed with the final data being formally
prepared for the IND filing. While most cancer treatments
today are derivatives of other compounds, Kevetrin is a
completely novel compound. Multidrug resistance, the principal
mechanism by which strains of cancer develop resistance to
chemotherapy drugs, is a major factor in the failure of many
forms of chemotherapy today and represents a huge need for
novel cancer treatments.
Kevetrin has been extensively studied in animal models of
lung, breast, and colon cancers, targeting carcinoma strains
that have proven resistant to standard therapies available on
the market today with the results showing greater tumor growth
delay than present therapies and strong efficacy in animal
models with increasing dosages. The impressive data obtained
during pre-clinical research has investors excited about human
trials as a history has shown that successful drug for the
treatment of specific lines of cancer can result in billions
of dollars in revenues.
Kevetrin, is a small molecule compound proprietary to the
Company. Its structure is distinct from other anti-cancer
agents currently on the market. Kevetrin was discovered by the
Company's founder, Dr. Krishna Menon, and has been studied
extensively (in vitro and in vivo) demonstrating potent
anti-cancer activity against various cancer cell lines.
Kevetrin's recent success in a series of animal model
experiments with drug-resistant cancer cell lines has
galvanized the Company to focus on Kevetrin's development
potential in this area.
The Company further proved the benefits of Kevetrin when they
announced that they had successfully completed animal model
tests on a taxane-resistant, estrogen receptor-negative breast
cancer human cell line, MDA-MB-435s, using its proprietary
pharmaceutical compound Kevetrin™. Tumor volume was reduced by
74% and tumor growth was delayed by more than 62% compared to
controls. In addition, both the tumor volume reduction and the
tumor growth delay were greater with Kevetrin than with
paclitaxel (Taxol) (p<0.01) or with cisplatin (p<0.01). The
experiment was repeated in order to increase the level of
confidence in the results, though cisplatin was not included
in the repeat experiment. The results in the repeated
experiment were similar to that in the initial test.
"In in-vivo testing Kevetrin continues to demonstrate
consistent success in fighting drug resistant cancers, the
leading cause of chemotherapy failure" said Mr. George Evans,
CEO of the Company. Mr. Evans continued: “We are optimistic
that Kevetrin will continue to progress on the developmental
pathway as a treatment for these very difficult cancers.”
This is very significant news, as it not only shows that
Kevetrin is beneficial in various types of cancers, but also
that it has been studied against several drug-resistant cancer
cell lines. One of the main causes of failure in the treatment
of cancer is the development of drug resistance by the cancer
cells. Since Kevetrin's structure is distinct from other
anti-cancer agents currently on the market, in laboratory
tests, it has been able to overcome that major hurdle.
Cellceutix's business strategy is well-described by their
company slogan “Compounds for Cures.” Cellceutix has kept a
“low profile” while developing their novel compounds, but the
Company name is spreading quickly through the industry and
investors are taking notice. Led by a team of pioneers in the
industry with over 100 years’ experience while holding high
level executive and research positions with companies such as
industry giants Pfizer and Eli Lilly, the Cellceutix team has
unparalleled leadership and research experience. The team
united with the specific goal of duplicating the incredible
results that they achieved for other companies for the
shareholders of Cellceutix.
Cellceutix has everything going for them, but they are still
significantly under the radar of most investors. The stock has
been trading in a range between $0.30 and $0.60 for the better
part of the last 9 months or so with a current price at around
$0.45. Looking at the stock from a technical perspective, the
first thing the charts are signalling is the tightening of the
bollinger bands, on little volume. This is a good sign as it
indicates that the stock has no significant buying or selling
pressure. With any important corporate release and some new
buying interest, CTIX could make a run upwards with just a
little bit of extra liquidity.
We have also prepared a
video chart evaluating CTIX, which discusses support and
resistance levels as well as what to look for going forward
with the stock price. The major support level for this stock
seems to be the $0.30 level, so setting stop losses in that
area would be strongly encouraged. There are a few resistance
points to look for with CTIX, and the video chart will discuss
all of the levels in more detail. Investors are encouraged to
view the video chart for CTIX by
clicking here. Remember, these are only our
interpretations of CTIX`s stock chart, and in the case of the
video chart, 123LearnToTrade.com's interpretation, and as
always, we encourage all investors to do their own due
diligence and consult with a financial advisor prior to making
any investment decisions.
There are other technical indicators signalling the
possibility of further upward movement, however with the low
liquidity it is difficult to truly
evaluate this stock from a technical perspective,
so with such strong fundamentals,
technical analysis should be put in the
passenger seat for this Company's stock.
Cellceutix Corp. (OTCBB:CTIX) is definitely a Company worth
exploring more. It may not be an overnight winner, but is
laying the groundwork for a long and prosperous corporate
future as it holds key patents and the rights to several drug
compounds that would make most Fortune 500 medical companies
jealous. The Company's lead drug, Kevetrin™, is in development
as a treatment for drug-resistant cancers, and KM-391, which
it is developing for the treatment of autism are among the
most prominent developments from the Company, and with medical
mergers and acquisitions commonplace, it is a Company that may
be on the radar screens of bigger fish in the medical pond.
CTIX's impressive management team certainly has the experience
and contacts to move this Company forward in a prosperous
fashion. For these reasons and more, AllPennyStocks.com
decided to spotlight Cellceutix Corp. (OTCBB:CTIX) as their
latest U.S. Company Spotlight and encourages investors to do
their own due diligence on this rapidly growing junior biotech
Company.
Kevetrin -
Lead Product
Excellent results in animal model experiments in
drug-resistant cancers
Kevetrin, the Company's lead
product candidate, is a small molecule compound proprietary
to the Company. Its structure is distinct from other
anti-cancer agents currently on the market. Kevetrin was
discovered by the Company's founder, Dr. Krishna Menon, and
has been studied extensively (in vitro and in vivo)
demonstrating potent anti-cancer activity against various
cancer cell lines. Kevetrin's recent success in a series of
animal model experiments with drug-resistant cancer cell
lines, has galvanized the Company to focus on Kevetrin's
development potential in this area. Kevetrin's primary
mechanism of action is as an AKT inhibitor but it also acts
as an alkylating agent and LTB4 inhibitor with
anti-angiogenic properties.
Some highlights of the studies conducted to date include:
- Small molecule drug that is structurally different from
anti-cancer agents currently on the market
- Primary mechanism of action is AKT inhibition
- Potent in vitro cytotoxicity against a panel of human
tumor cell lines
- Demonstrated success in more than 5,000 small animal
tests, achieving significant delays in tumor growth compared
to controls in breast, prostate and colon cancer tumors.
- In animal tests of a head and neck cancer cell line,
delay in tumor growth was significantly increased by 14 days
with Kevetrin alone (about the same as with radiation alone)
but when Kevetrin was administered in conjunction with
radiation, tumor growth delay increased by 36 days, more
than two-fold compared to controls
- In small animal tests, Kevetrin was well tolerated.
The Company is now conducting
additional studies to allow them to
request permission from the FDA to
begin studies in humans.
Chemistry
Kevetrin is a small molecule that is different in structure
from all currently marketed cancer drugs. It is water-soluble
and simple to synthesize from commercially available starting
materials. The Company expects
that it will initially be administered as an intravenous (IV)
product.
Patent Protection
Cellceutix filed a patent application covering Kevetrin in
May, 2009. The patent application claims pharmaceutical
formulations of Kevetrin in addition to novel compounds having
similar structures to Kevetrin that may have potential as drug
development candidates. The application also covers the use of
Kevetrin and the other compounds in various disease states,
including cancers. Cellceutix plans to file patent
applications in other countries within a year of the U.S.
filing.
Drug-Resistant Cancer Cell Lines
One of the main causes of failure in the treatment of cancer
is the development of drug resistance by the cancer cells.
Kevetrin has been studied against several drug-resistant
cancer cell lines.
Lung Cancer
Kevetrin has been studied in animal models using a number of
drug-resistant cell lines. Kevetrin was studied in two cell
lines of multi-drug resistant lung cancer. In two studies with
the A549 cell line, Kevetrin showed average tumor growth delay
of 72% and average tumor volume reduction of 81% compared to
controls. Both tumor growth delay and tumor volume reduction
were also significantly greater with Kevetrin than with
paclitaxel (Taxol) (p<0.001).
In two studies with the NCI-H1975 cell line of multi-drug
resistant lung cancer, Kevetrin showed average tumor growth
delay of 149% and tumor volume reduction of 94% compared to
controls. Both tumor growth delay and tumor volume reduction
were greater with Kevetrin than with paclitaxel (p<0.001).
Other Cancer Cell Lines:
Head and Neck Cancer
Kevetrin was studied in multiple experiments alone and in
conjunction with radiation against the SCC-15 cell line of
head and neck cancer. Kevetrin alone showed an average tumor
growth delay of 45% compared to controls, similar to radiation
alone. When administered in conjunction with radiation,
Kevetrin showed an average tumor growth delay of 116%.
Colon Cancer
Kevetrin was studied in two experiments alone and in
combination with 5-FU against the HT-29 cell line of colon
cancer. Kevetrin alone demonstrated average tumor growth delay
of 43% compared to controls. 5-FU alone showed an average
tumor growth delay of 20%. The combination of Kevetrin and
5-FU resulted in an average tumor growth delay of 97%.
Breast Cancer
In a study with the MDA-MB-231 breast cancer cell line,
Kevetrin demonstrated tumor growth delay of 90% compared to
controls.
Prostate Cancer
Kevetrin was studied against the PC-3 cell line of prostate
cancer. In two studies, Kevetrin demonstrated an average tumor
growth delay of 54% compared to controls, while cisplatin
showed and average tumor growth delay of 49%.
Recent News and Press Releases
Kevetrin Demonstrates Significant Results in the Treatment of
Multi-Drug Resistant Cancer Cells
Marketwire (Mon, Jun 21)
New Autism Drug Research by Cellceutix on Compound KM-391
Results in Significant Behavioral Changes; Chief Scientific
Officer Sees Potential for Company to Emerge as Industry
Leader as Pharmas Strive for Revolutionary Autism Treatments
Marketwire (Mon, Jun 14)
Cellceutix Responds to Public Support by Expediting Autism
Studies; Completes Two Required Safety Pharmacology Studies
for Its Cancer Compound
Marketwire (Mon, Jun 7)
Cellceutix CFO Discusses Autism Drug, Kevetrin(TM) and Company
Progressions With CEOCFO Interviews and News
Marketwire (Thu, Jun 3)
Cellceutix Signs Agreements for Kevetrin(TM) Phase 1 Support;
Company Continues to Advance Kevetrin Toward Human Studies
Targeting Drug Resistant Cancers
Marketwire (Mon, May 24)
Cellceutix Files Foreign Patent Application in PCT and Other
Key Countries for Its Flagship Cancer Compound
Marketwire (Tue, May 18)
Recent Announcements Suggest Cellceutix Is Well Positioned
With Autism Compound; Pfizer and Novartis Announcements
Indicate Interest in Autism by Major Companies
Marketwire (Wed, May 12)
Cellceutix Presents Poster Session at AACR; Important New Data
on Kevetrin(TM) in Resistant Lung Cancer Model Show Dose
Response; No Tumor Cell Resistance With Second Cycle
Marketwire (Wed, Apr 21)
Management
Chief Executive Officer, Chairman of the Board of
Directors- George W. Evans, JD, MBA; George Evans has
more than 25 years experience in the Pharmaceutical industry.
He worked in a number of positions for Pfizer Inc, ending his
career there as General Counsel for Pfizer's worldwide
prescription drug unit, and a member of the unit's leadership
team. During his time at Pfizer Mr. Evans gained experience in
all aspects of the pharmaceutical business, from early stage
research to end-of-life-cycle strategies. Mr. Evans also
played a key part in negotiating several major transactions
for Pfizer. In addition to his direct business experience, Mr.
Evans has a wealth of experience in building and integrating
organizations while maintaining the highest levels of
performance. Mr. Evans was a member of the Editorial Advisory
Board and the Finance Committee of the Food and Drug Law
Institute and a member of the Board of the City Bar Fund. He
is a graduate of Williams College and Columbia University's
Law and Business schools.
President, Chief Scientific Officer, Board of Directors -
Dr. Krishna Menon RCM, PhD, VMD - Dr. Krishna Menon has
more than 35 years in drug development for academia and
industry. Originally trained as a veterinary surgeon, Menon
began his career as Chief Government Veterinarian for a major
Parish in Jamaica. He segued to a three-year stint as Director
of Agriculture for the Cayman Islands, in the British
Caribbean and, in 1982, moved to the Dana Farber Cancer
Research Institute, where he worked under the direction of Dr.
Emil Frei. Two years later, he earned his PhD in Pharmacology
from Harvard University. Menon's PhD work focused on
anti-folate therapy of various cancers. Menon was a Research
Scientist at Dana Farber from 1985 to 1990 and Senior Research
Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals
(Miles Laboratories) from 1991 to 1993. After a year operating
his own veterinary oncology and drug development consultancy
practice, Menon was tapped Group Leader, Cancer In Vivo
Research and Clinical Development, for Eli Lilly (1995-2001),
where he played a key role in lead selection and pre-clinical
development of Gemzar and Alimta which in 2006 had over 2.1
billion dollars ($2,100,000,000) in sales, and is a
co-developer of another seven compounds currently in
late-stage clinical development. In 1999, Lilly honored Menon
with the President's Recognition Award, an award not bestowed
annually but rather on only special occasions.
Chief Financial Officer, Board of Directors- Leo Ehrlich,
CPA Served as Chief Financial Officer (CFO) of
Cellceutix Pharma since inception in June 2007. Following the
acquisition, he was appointed CFO and a director. Mr. Ehrlich was also
founder of Nanoviricides, Inc. (OTCBB:NNVC). That Company
started with limited trading volume and a very small market
cap and has a present market cap of over $100 million dollars. Mr. Ehrlich is a Certified Public Accountant
and received his BBA from Bernard Baruch College of the City
University of New York.
Contact
Cellceutix Corp.
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-633-3623
Fax: 978-921-6564
Email:
info@cellceutix.com
FORWARD LOOKING STATEMENTS
This report includes forward-looking
statements that reflect Cellceutix Corp. current
expectations about its future results, performance,
prospects and opportunities.
Cellceutix Corp. has
tried to identify these forward-looking statements by using
words and phrases such as "may," "will," "expects,"
"anticipates," "believes," "intends," "estimates," "plan,"
"should," "typical," "preliminary," "we are confident" or
similar expressions. These forward-looking statements are
based on information currently available and are subject to
a number of risks, uncertainties and other factors that
could cause Cellceutix Corp.'s actual results,
performance, prospects or opportunities to differ materially
from those expressed in, or implied by, these
forward-looking statements. These risks, uncertainties and
other factors include, without limitation, the Company's
growth expectations and ongoing funding requirements, and
specifically, the Company's growth prospects with scalable
customers, and those outlined above. Other risks include the
Company's limited operating history, the Company's history
of operating losses, consumers' acceptance, the Company's
use of licensed technologies, risk of increased competition,
the potential need for additional financing, the terms and
conditions of any financing that is consummated, the limited
trading market for the Company's securities, the possible
volatility of the Company's stock price, the concentration
of ownership, and the potential fluctuation in the Company's
operating results.
Disclaimer
AllPennyStocks.com feature stock reports
are intended to be stock ideas, NOT recommendations. Please
do your own research before investing. It is crucial that
you at least look at current SEC filings and read the latest
press releases. Information contained in this report was
extracted from current documents filed with the SEC, the
company web site and other publicly available sources deemed
reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document
contains forward-looking statements, particularly as related
to the business plans of the Company, within the meaning of
Section 27A of the Securities Act of 1933 and Sections 21E
of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results
may differ materially from the Company's expectations and
estimates. This is an advertisement for
Cellceutix Corp. The purpose of this advertisement, like any
advertising, is to provide coverage and awareness for the
company. The information provided in this advertisement is
not intended for distribution to, or use by, any person or
entity in any jurisdiction or country where such
distribution or use would be contrary to law or regulation
or which would subject us to any registration requirement
within such jurisdiction or country.
© 1999-2010 AllPennyStocks.com. All rights
reserved. AllPennyStocks.com is not a Registered
Broker/Dealer or Financial Advisor, nor do we hold ourselves
out to be. All materials presented on our web site and
individual reports released to the public through this web
site, e-mail or any other means of transmission are not to
be regarded as investment advice and are only for
informative purposes. Before making a purchase or sale of
any securities featured on our web site or mentioned in our
reports, we strongly encourage and recommend consultation
with a registered securities representative. This is not to
be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to
profile involve a degree of investment risk and volatility.
Particularly Small-Caps and OTC-BB stocks. All investors are
cautioned that they may lose all or a portion of their
investment if they decide to make a purchase in any of our
profiled companies. Past performance of our profiled stocks
is not indicative of future results. The accuracy or
completeness of the information on our web site or within
our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are
expressed as of the date the profile is posted on site and
are subject to change without notice. No investor should
assume that reliance on the views, opinions or
recommendations contained herein will produce profitable
results. AllPennyStocks.com may hold positions in securities
mentioned herein, and may make purchases or sales in such
securities featured on our web site or within our reports.
In order to be in full compliance with the Securities Act of
1933, Section 17(b), AllPennyStocks.com will disclose in
it's disclaimer, what, if any compensation was received for
our efforts in researching, presenting and disseminating
this information to our subscriber database and featuring
the report on the AllPennyStocks.com web site.
AllPennyStocks.com has been compensated
ten thousand dollars by
the Company in
September 2009 and seven thousand five hundred dollars in
June 2010 for its efforts in presenting the
CTIX profile
on its web site and distributing it to its database of
subscribers as well as other services. AllPennyStocks.com
may decide to purchase or sell shares on a voluntary basis
in the open market before, during or after the profiling
period of this report. As of the profile date, no shares
have been sold. Information presented on our web site and
within our reports contain "forward looking statements"
within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934.
Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans,
projections, objectives, goals, assumptions or future events
or performance are not statements of historical fact and may
be "forward looking statements." Forward looking statements
are based on expectations, estimates and projections at the
time the statements are made that involve a number of risks
and uncertainties which could cause actual results or events
to differ materially from those presently anticipated.
Forward looking statements in this action may be identified
through the use of words such as “expects’”, “will,”
“anticipates,” “estimates, “believes,” or that by statements
indicating certain actions “may,” “could,” or “might” occur.
THE READER SHOULD VERIFY ALL CLAIMS AND DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES
MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE
AND CARRIES A HIGH DEGREE OF RISK.
We encourage our readers to invest
carefully and read the investor information available at the
web sites of the Securities and Exchange Commission (SEC)
at:
http://www.sec.gov and/or the National Association of
Securities Dealers (NASD) at:
http://www.nasd.com. Readers can review all public
filings by companies at the SEC's EDGAR page. The NASD has
published information on how to invest carefully at its web
site.
|
|